RNAZ
Transcode Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.67M
P/E Ratio
—
EPS
$-236.52
Beta
1.50
52W High
$22.03
52W Low
$6.08
50-Day MA
$9.59
200-Day MA
$9.89
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-17.00M |
| Operating Margin | 0.00% |
| Return on Equity | -1763.00% |
| Return on Assets | -232.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.71 |
| Price-to-Book | 5.53 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 916,970 |
| Float | 832,420 |
| % Insiders | 9.22% |
| % Institutions | 5.67% |
Data last updated: 4/9/2026